
Patient Enrollment Completed in the Phase 3 Trial for Negative Symptoms of Schizophrenia
Minerva Neurosciences announced it has completed phase 3 patient randomization in a multicenter trial of roluperidone.
NEWS BRIEF
The biopharmaceutical company
For the trial, 515 patients have been randomized in double-blind, parallel, placebo-controlled groups across clinical sites in Europe and the US. The 12-week study will evaluate the safety and efficacy of roluperidne in both 32 mg and 64 mg doses, measured by the Marder negative symptoms factor score of the Positive and Negative Syndrome Scale.
As reported in a
Executive Chairman and Chief Executive Officer of Minerva Neurosciences’s Remy Luthringer, PhD, calls this step a “major milestone” in treating negative symptoms, and the company hopes to focus on addressing unmet needs in treating CNS disorders.
References:
1. Velligan DI, Alphs LD. Negative Symptoms in Schizophrenia: An Update on Identification and Treatment. Psychiatric Times. November 24, 2014.
2. Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia [press release] February 5, 2020.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.